Characterization of a selective CaMKII peptide inhibitor

Isabel Gomez-Monterrey, Marina Sala, Maria Rosaria Rusciano, Sara Monaco, Angela Serena Maione, Guido Iaccarino, Paolo Tortorella, Anna Maria D'Ursi, Mario Scrima, Alfonso Carotenuto, Giuseppe De Rosa, Alessia Bertamino, Ermelinda Vernieri, Paolo Grieco, Ettore Novellino, Maddalena Illario, Pietro Campiglia

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Analogs of potent CaMKinase II inhibitor, CaM-KNtide, were prepared to explore new structural requirements for the inhibitory activity. The full potency of CaMKII inhibition by CaM-KIINα is contained within a minimal region of 19 amino acids. Here, analysis of the homologous CaM-KIINβ showed that a 17 mer peptide (CN17β) was the shortest sequence that still retained useful inhibitory potency. Ala substitution of almost any residue of CN17β dramatically reduced potency, except for substitution of P3, R14, and V16. Fusion with the tat sequence generated the cell-penetrating inhibitor version tat-5. This tat-5 fusion peptide maintained selectivity for CaMKII over CaMKI and CaMKIV, and appeared to slightly further enhance potency (IC 50 ∼30 nM). Within a breast cancer cell line and in primary human fibroblasts, tat-5 inhibited the Erk signaling pathway and proliferation without any measurable cytotoxicity. Structural analysis of CN17β by CD and NMR indicated an α-helix conformation in the Leu6-Arg11 segment well overlapping with the crystal structure of 21-residue segment of CaM-KNtide bound to the kinase domain of CaMKII.

Original languageEnglish
Pages (from-to)425-434
Number of pages10
JournalEuropean Journal of Medicinal Chemistry
Volume62
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Calcium-Calmodulin-Dependent Protein Kinase Type 2
Peptides
Substitution reactions
Fusion reactions
Fibroblasts
Cytotoxicity
Structural analysis
Conformations
Phosphotransferases
Crystal structure
Cells
Nuclear magnetic resonance
Breast Neoplasms
Amino Acids
Cell Line

Keywords

  • Ca/calmodulin-dependent protein kinase
  • CaM-KNtide analogs
  • CaMKinase II inhibitor
  • Cell growth inhibition
  • Protein kinase

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Gomez-Monterrey, I., Sala, M., Rusciano, M. R., Monaco, S., Maione, A. S., Iaccarino, G., ... Campiglia, P. (2013). Characterization of a selective CaMKII peptide inhibitor. European Journal of Medicinal Chemistry, 62, 425-434. https://doi.org/10.1016/j.ejmech.2012.12.053

Characterization of a selective CaMKII peptide inhibitor. / Gomez-Monterrey, Isabel; Sala, Marina; Rusciano, Maria Rosaria; Monaco, Sara; Maione, Angela Serena; Iaccarino, Guido; Tortorella, Paolo; D'Ursi, Anna Maria; Scrima, Mario; Carotenuto, Alfonso; De Rosa, Giuseppe; Bertamino, Alessia; Vernieri, Ermelinda; Grieco, Paolo; Novellino, Ettore; Illario, Maddalena; Campiglia, Pietro.

In: European Journal of Medicinal Chemistry, Vol. 62, 04.2013, p. 425-434.

Research output: Contribution to journalArticle

Gomez-Monterrey, I, Sala, M, Rusciano, MR, Monaco, S, Maione, AS, Iaccarino, G, Tortorella, P, D'Ursi, AM, Scrima, M, Carotenuto, A, De Rosa, G, Bertamino, A, Vernieri, E, Grieco, P, Novellino, E, Illario, M & Campiglia, P 2013, 'Characterization of a selective CaMKII peptide inhibitor', European Journal of Medicinal Chemistry, vol. 62, pp. 425-434. https://doi.org/10.1016/j.ejmech.2012.12.053
Gomez-Monterrey I, Sala M, Rusciano MR, Monaco S, Maione AS, Iaccarino G et al. Characterization of a selective CaMKII peptide inhibitor. European Journal of Medicinal Chemistry. 2013 Apr;62:425-434. https://doi.org/10.1016/j.ejmech.2012.12.053
Gomez-Monterrey, Isabel ; Sala, Marina ; Rusciano, Maria Rosaria ; Monaco, Sara ; Maione, Angela Serena ; Iaccarino, Guido ; Tortorella, Paolo ; D'Ursi, Anna Maria ; Scrima, Mario ; Carotenuto, Alfonso ; De Rosa, Giuseppe ; Bertamino, Alessia ; Vernieri, Ermelinda ; Grieco, Paolo ; Novellino, Ettore ; Illario, Maddalena ; Campiglia, Pietro. / Characterization of a selective CaMKII peptide inhibitor. In: European Journal of Medicinal Chemistry. 2013 ; Vol. 62. pp. 425-434.
@article{fa594d5447d0475c9b5d51a742a42198,
title = "Characterization of a selective CaMKII peptide inhibitor",
abstract = "Analogs of potent CaMKinase II inhibitor, CaM-KNtide, were prepared to explore new structural requirements for the inhibitory activity. The full potency of CaMKII inhibition by CaM-KIINα is contained within a minimal region of 19 amino acids. Here, analysis of the homologous CaM-KIINβ showed that a 17 mer peptide (CN17β) was the shortest sequence that still retained useful inhibitory potency. Ala substitution of almost any residue of CN17β dramatically reduced potency, except for substitution of P3, R14, and V16. Fusion with the tat sequence generated the cell-penetrating inhibitor version tat-5. This tat-5 fusion peptide maintained selectivity for CaMKII over CaMKI and CaMKIV, and appeared to slightly further enhance potency (IC 50 ∼30 nM). Within a breast cancer cell line and in primary human fibroblasts, tat-5 inhibited the Erk signaling pathway and proliferation without any measurable cytotoxicity. Structural analysis of CN17β by CD and NMR indicated an α-helix conformation in the Leu6-Arg11 segment well overlapping with the crystal structure of 21-residue segment of CaM-KNtide bound to the kinase domain of CaMKII.",
keywords = "Ca/calmodulin-dependent protein kinase, CaM-KNtide analogs, CaMKinase II inhibitor, Cell growth inhibition, Protein kinase",
author = "Isabel Gomez-Monterrey and Marina Sala and Rusciano, {Maria Rosaria} and Sara Monaco and Maione, {Angela Serena} and Guido Iaccarino and Paolo Tortorella and D'Ursi, {Anna Maria} and Mario Scrima and Alfonso Carotenuto and {De Rosa}, Giuseppe and Alessia Bertamino and Ermelinda Vernieri and Paolo Grieco and Ettore Novellino and Maddalena Illario and Pietro Campiglia",
year = "2013",
month = "4",
doi = "10.1016/j.ejmech.2012.12.053",
language = "English",
volume = "62",
pages = "425--434",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Characterization of a selective CaMKII peptide inhibitor

AU - Gomez-Monterrey, Isabel

AU - Sala, Marina

AU - Rusciano, Maria Rosaria

AU - Monaco, Sara

AU - Maione, Angela Serena

AU - Iaccarino, Guido

AU - Tortorella, Paolo

AU - D'Ursi, Anna Maria

AU - Scrima, Mario

AU - Carotenuto, Alfonso

AU - De Rosa, Giuseppe

AU - Bertamino, Alessia

AU - Vernieri, Ermelinda

AU - Grieco, Paolo

AU - Novellino, Ettore

AU - Illario, Maddalena

AU - Campiglia, Pietro

PY - 2013/4

Y1 - 2013/4

N2 - Analogs of potent CaMKinase II inhibitor, CaM-KNtide, were prepared to explore new structural requirements for the inhibitory activity. The full potency of CaMKII inhibition by CaM-KIINα is contained within a minimal region of 19 amino acids. Here, analysis of the homologous CaM-KIINβ showed that a 17 mer peptide (CN17β) was the shortest sequence that still retained useful inhibitory potency. Ala substitution of almost any residue of CN17β dramatically reduced potency, except for substitution of P3, R14, and V16. Fusion with the tat sequence generated the cell-penetrating inhibitor version tat-5. This tat-5 fusion peptide maintained selectivity for CaMKII over CaMKI and CaMKIV, and appeared to slightly further enhance potency (IC 50 ∼30 nM). Within a breast cancer cell line and in primary human fibroblasts, tat-5 inhibited the Erk signaling pathway and proliferation without any measurable cytotoxicity. Structural analysis of CN17β by CD and NMR indicated an α-helix conformation in the Leu6-Arg11 segment well overlapping with the crystal structure of 21-residue segment of CaM-KNtide bound to the kinase domain of CaMKII.

AB - Analogs of potent CaMKinase II inhibitor, CaM-KNtide, were prepared to explore new structural requirements for the inhibitory activity. The full potency of CaMKII inhibition by CaM-KIINα is contained within a minimal region of 19 amino acids. Here, analysis of the homologous CaM-KIINβ showed that a 17 mer peptide (CN17β) was the shortest sequence that still retained useful inhibitory potency. Ala substitution of almost any residue of CN17β dramatically reduced potency, except for substitution of P3, R14, and V16. Fusion with the tat sequence generated the cell-penetrating inhibitor version tat-5. This tat-5 fusion peptide maintained selectivity for CaMKII over CaMKI and CaMKIV, and appeared to slightly further enhance potency (IC 50 ∼30 nM). Within a breast cancer cell line and in primary human fibroblasts, tat-5 inhibited the Erk signaling pathway and proliferation without any measurable cytotoxicity. Structural analysis of CN17β by CD and NMR indicated an α-helix conformation in the Leu6-Arg11 segment well overlapping with the crystal structure of 21-residue segment of CaM-KNtide bound to the kinase domain of CaMKII.

KW - Ca/calmodulin-dependent protein kinase

KW - CaM-KNtide analogs

KW - CaMKinase II inhibitor

KW - Cell growth inhibition

KW - Protein kinase

UR - http://www.scopus.com/inward/record.url?scp=84873433183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873433183&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2012.12.053

DO - 10.1016/j.ejmech.2012.12.053

M3 - Article

C2 - 23395965

AN - SCOPUS:84873433183

VL - 62

SP - 425

EP - 434

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -